Lantern Pharma Inc. (NASDAQ: LTRN) announced completion of its Phase 1a clinical trial for LP-184, meeting all primary endpoints with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE